Skip to content

K-Dense-AI/scientific-agent-skills / skills/pkpd-modeling

pkpd-modeling

Verified

Pharmacokinetic and pharmacodynamic modelling and simulation - non-compartmental analysis, compartmental and population PK, PK/PD and exposure-response, TMDD, PBPK orientation, bioequivalence, allometric scaling and first-in-human dose, drug interaction prediction, and Bayesian therapeutic drug monitoring. Use when analysing concentration-time data, deriving exposure metrics, fitting PK or PD models, or evaluating dosing regimens. Triggers include "pharmacokinetics", "pharmacodynamics", "PK/PD", "NCA", "non-compartmental", "AUC", "Cmax", "lambda z", "half-life", "clearance", "volume of distribution", "compartmental model", "population PK", "popPK", "NONMEM", "nlmixr2", "Pharmpy", "Monolix", "exposure-response", "Emax", "EC50", "indirect response", "effect compartment", "TMDD", "PBPK", "bioequivalence", "RSABE", "ABEL", "allometric scaling", "first-in-human", "MABEL", "drug-drug interaction", "DDI", "ICH M12", "concentration-QTc", "therapeutic drug monitoring", "MIPD", and "dosing regimen".

references/bioequivalence.md

View on GitHub
# Bioequivalence: design before arithmetic

## Conventional average BE

Log-transform each prespecified positive PK metric and estimate the test/reference contrast under
the actual design. Back-transform the 90% confidence interval. Conventional 80–125% limits are
not universal; select metric, design, region and product-specific guidance before analyzing data.

The helper supports complete two-period RT/TR crossover and independent parallel observations.
Crossover requires exactly one T and one R per subject, correct period/sequence labels and both
sequences. It accounts for sequence in the within-subject contrasts. Parallel analysis requires one
value per subject. Neither path handles missing-period replicate data, carryover, multiple groups,
adaptive designs or repeated independent-looking values.

## Reference scaling

Replicate BE needs a design-specific statistical model. Period/sequence-adjusted reference
variance and treatment-contrast uncertainty cannot generally be obtained by pooling each subject's
raw replicate variance or averaging repeats. The CLI therefore rejects replicate analysis and
reference scaling; it must not output a regulatory pass from those shortcuts.

FDA's May 2026 guidance replaces the 2001 statistical guidance. Appendix G supplies HVD models:
`sWR >= 0.294`, a reference-scaled upper-bound criterion and an 80–125% point-estimate constraint.
In its scalar bound, `x=estimate²-SE²` and the negative variance term's bound uses the **0.95**
chi-square quantile. The retained `rsabe_bound` helper only combines externally justified scalar
inputs; it cannot fit the required design or determine applicability. FDA NTI analysis is distinct;
`--nti` merely changes this CLI's conventional limits.
[FDA statistical guidance](https://www.fda.gov/media/163638/download).

EMA widening for eligible highly variable Cmax uses `exp(±0.760*sWR)`, capped at CVwR 50%, with
80–125% point-estimate constraints and prespecified clinical justification. It is not generic
permission to widen AUC or NTI limits. ABEL and FDA RSABE are different procedures. The scalar
`abel_limits` is arithmetic only; use a qualified design-specific implementation.
[EMA BE guideline](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf).

## Planning

Power depends on GMR, within-subject CV, allocation, design, dropout and analysis assumptions.
The bundled calculation integrates over estimated variance using a finite quantile grid. It is a
numerical approximation, not an exact Owen-Q implementation. With balanced 2x2, CV 30%, GMR 0.95
and target power 80%, it returns N=40 evaluable participants in synthetic checks. Probe sensitivity,
then independently check the intended design using [PowerTOST](https://cran.r-project.org/web/packages/PowerTOST/vignettes/vignette.html).

## Current harmonization boundary

ICH M13A concerns immediate-release solid oral products; EU implementation began 25  January 2025.
Regional provisions for replicate and NTI studies still require attention. M13B is now EMA Step 5,
adopted  September 2026 with effect  March 2027; it concerns additional-strength biowaivers, not HVD
statistics. M13C remains under development. See [regulatory guidance](regulatory-guidance.md).
slack-gif-creatoranthropics/skillsKnowledge and utilities for creating animated GIFs optimized for Slack. Provides constraints, validation tools, and animation concepts. Use when users request animated GIFs for Slack like "make me a GIF of X doing Y for Slack."Stars: 198kUpdated Claude CodeCodexVerifiedInstall
ponytailDietrichGebert/ponytailLazy senior dev mode for any coding task: the smallest change that fully solves it, and a reply a busy human understands in one read.Stars: 194kUpdated Claude CodeCodexVerifiedInstall
ponytail-debtDietrichGebert/ponytailHarvest every shortcut: comment into one debt ledger, so deferrals get tracked instead of forgotten. One-shot report.Stars: 194kUpdated Claude CodeCodexVerifiedInstall
ponytail-debtDietrichGebert/ponytailList every `shortcut:` comment (and older `ponytail:` ones) as a debt ledger. One-shot report, changes nothing. Use for "ponytail debt", "what did ponytail defer", "list the shortcuts", /ponytail-debt.Stars: 194kUpdated Claude CodeCodexVerifiedInstall